Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.69 |
| ▸ | HTR1D | P28221 | 13/20 | 0.69 |
| ▸ | HTR1B | P28222 | 13/20 | 0.69 |
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6720399 | 0.87 | MAPT (0.59) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL6717656 | 0.87 | HTR1A (0.64) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL6718241 | 0.87 | HTR1A (0.69) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL6714842 | 0.85 | HTR1A (0.64) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL6261942 | 0.85 | HTR1A (0.48) | HTR1AHTR1DHTR1B | |
| SCHEMBL6714874 | 0.85 | HTR1A (0.52) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL6717731 | 0.85 | HTR1A (0.56) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL6714770 | 0.85 | HTR1A (0.56) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL6714916 | 0.84 | HTR1A (0.55) | HTR1AHTR1DHTR1BHTR2CHTR6 | |
| SCHEMBL6717515 | 0.84 | HTR1A (0.55) | HTR1AHTR1DHTR1BHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313477-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-03-03 | — | — | EP | claimed |
| US-20040038982-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | claimed |
| EP-1313477-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2003-05-28 | — | — | EP | claimed |
| WO-2002005819-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-24 | — | — | WO | claimed |
| EP-1313477-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040038982-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
| EP-1313477-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002005819-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038982-A1 | Compounds and methods | CCR5, CXCR3, CCR2 | HTR1A 651/4885HTR1D 887/4885HTR1B 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.